- Home
- ANIX vs CRDF Comparison
ANIX vs CRDF Comparison
Compare ANIX & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANIX | CRDF |
|---|---|---|
| Founded | 1982 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 114.5M |
| IPO Year | 2013 | 2012 |
Fundamental Metrics
Financial Performance| Metric | ANIX | CRDF |
|---|---|---|
| Price | $2.95 | $1.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $9.00 | ★ $9.63 |
| AVG Volume (30 Days) | 141.7K | ★ 989.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.82 | ★ 27.37 |
| EPS | ★ N/A | N/A |
| Revenue | $210,000.00 | ★ $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $2.33 | $1.48 |
| 52 Week High | $5.46 | $4.56 |
Technical Indicators
Market Signals| Indicator | ANIX | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 45.34 | 51.82 |
| Support Level | $2.69 | $1.48 |
| Resistance Level | $3.00 | $2.41 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 70.42 | 78.64 |
Price Performance
Historical ComparisonAbout ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.